Alembic Pharmaceuticals Ltd - 533573 - Alembic Pharmaceuticals Receives USFDA Final Approval For Doxorubicin Hydrochloride Liposome Injection

Alembic Pharmaceuticals Ltd.

NSE: APLLTD | BSE: 533573 | ISIN: INE901L01018 | Industry: Pharmaceuticals
| Mid-range Performer

999.0000 10.50 (1.06%)

NSE Jul 03, 2025 13:33 PM

37.76% Gain from 52W Low

Volume: 339.2K

High vol. this week

Alembic Pharmaceuticals Ltd.

29 Jun 2025

999.00

1.06%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Alembic Pharmaceuticals Receives USFDA Final Approval For Doxorubicin Hydrochloride Liposome …

BSE India

Please find enclosed the USFDA Approval received for Doxorubicin Hydrochloride Liposome Injection

More from Alembic Pharmaceuticals Ltd.

Recommended

Market trades higher, Nykaa's promoter reportedly plans to sell a 2.1% stake worth $140 mn

Trendlyne Marketwatch | 03 Jul 2025, 01:04PM

Is India getting old before getting rich? | Screener: All star stocks with high five year returns

The Baseline | 03 Jul 2025, 12:14PM

Earnings Call Transcript - Q1FY21 for Alembic Pharmaceuticals